文献速递冠心病心律失常

急性冠脉综合征中替格瑞洛联合阿司匹林的获益与风险:GLOBAL LEADERS 试验事后分析

Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.
PubMed 文献 · JAMA Cardiol · 2019-01-01

该研究为 GLOBAL LEADERS 随机开放标签优效性试验的非预设事后分析,纳入 7487 例接受 PCI 的急性冠脉综合征患者,比较术后 31 至 365 天替格瑞洛单药与替格瑞洛联合阿司匹林的结局。结果显示联合阿司匹林未显著减少缺血事件,但出血风险显著增加,提示无阿司匹林策略值得进一步研究。

要点

  • ACS 患者 PCI 术后 1 至 12 个月,替格瑞洛单药组主要缺血终点数值低于联合阿司匹林组但未达统计学显著。
  • 替格瑞洛单药组 BARC 3 或 5 型出血风险显著低于联合阿司匹林组。
  • 结果属探索性、假设生成性,支持进一步开展无阿司匹林抗血小板策略的试验。

核心结论

  • 在 ACS 患者 PCI 术后 1 至 12 个月,替格瑞洛基础上加用阿司匹林与出血风险增加相关,且似乎未在缺血事件上增加替格瑞洛的获益。
  • 作者强调该发现为探索性和假设生成性,为进一步评估无阿司匹林抗血小板策略的试验奠定基础。

研究设计与样本

  • GLOBAL LEADERS 随机开放标签优效性试验的非预设事后分析,涉及不同国家 130 家二级/三级医院。
  • 实验组 3750 例接受阿司匹林联合替格瑞洛 1 个月后替格瑞洛单药治疗 23 个月;参照组 3737 例接受阿司匹林联合氯吡格雷(稳定冠心病)或替格瑞洛(ACS)12 个月后阿司匹林单药治疗 12 个月。
  • 本分析评估随机化后 31 至 365 天内的临床结局,比较替格瑞洛单药与替格瑞洛联合阿司匹林。

临床怎么用

  • ACS 患者 PCI 术后 1 个月后,可考虑评估停用阿司匹林、采用替格瑞洛单药的可能性以减少出血风险。
  • 该分析为事后探索性结果,临床决策需结合患者缺血与出血风险个体化判断,不应直接改变指南推荐。

局限性

  • 本研究为非预设事后分析,结果应视为探索性和假设生成性。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The role of aspirin as part of antiplatelet regimens in acute coronary syndromes (ACS) needs to be clarified in the context of newer potent P2Y12 antagonists. OBJECTIVE: To evaluate the benefit and risks of aspirin in addition to ticagrelor among patients with ACS beyond 1 month after percutaneous coronary intervention (PCI). DESIGN, SETTING, AND PARTICIPANTS: This is a nonprespecified, post hoc analysis of GLOBAL LEADERS, a randomized, open-label superiority trial comparing 2 antiplatelet treatment strategies after PCI. The trial included 130 secondary/tertiary care hospitals in different countries, with 15 991 unselected patients with stable coronary artery disease or ACS undergoing PCI. Patients had outpatient visits at 1, 3, 6, 12, 18, and 24 months after index procedure. INTERVENTIONS: The experimental group received aspirin plus ticagrelor for 1 month followed by 23-month ticagrelor monotherapy; the reference group received aspirin plus either clopidogrel (stable coronary artery disease) or ticagrelor (ACS) for 12 months, followed by 12-month aspirin monotherapy. In this analysis, we examined the clinical outcomes occurring between 31 days and 365 days after randomization, specifically in patients with ACS who, within this time frame, were assigned to receive either ticagrelor alone or ticagrelor and aspirin. MAIN OUTCOMES AND MEASURES: The primary outcome was the composite of all-cause death or new Q-wave myocardial infarction. RESULTS: Of 15 968 participants, there were 7487 patients with ACS enrolled; 3750 patients were assigned to the experimental group and 3737 patients to the reference group. Between 31 and 365 days after randomization, the primary outcome occurred in 55 patients (1.5%) in the experimental group and in 75 patients (2.0%) in the reference group (hazard ratio [HR], 0.73; 95% CI, 0.51-1.03; P = .07); investigator-reported Bleeding Academic Research Consortium-defined bleeding type 3 or 5 occurred in 28 patients (0.8%) in the experimental group and in 54 patients (1.5%) in the reference arm (HR, 0.52; 95% CI, 0.33-0.81; P = .004). CONCLUSIONS AND RELEVANCE: Between 1 month and 12 months after PCI in ACS, aspirin was associated with increased bleeding risk and appeared not to add to the benefit of ticagrelor on ischemic events. These findings should be interpreted as exploratory and hypothesis generating; however, they pave the way for further trials evaluating aspirin-free antiplatelet strategies after PCI. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01813435.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Tomaniak M, Chichareon P, Onuma Y, et al. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial. JAMA Cardiol. 2019. PMID: 31557763. doi:10.1001/jamacardio.2019.3355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。